As previously reported, BofA/Merrill upgraded Universal Health to Buy from Neutral and raised its price target to $155 from $128. Analyst Kevin Fischbeck expects the company’s psych business to reaccelerate and reach its 5% growth goal as it nears the Department of Justice settlement and easier comps in 2H. The analyst also expects Universal’s acute care business to continue to perform better given exposure to higher growth markets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.